Every 10-Q that Summit Therapeutics Inc. (SMMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SMMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMMT filings page.
Summit Therapeutics Inc. reported a net loss of $215,700 for the three months and $405,124 for the six months ended June 30, 2026, compared with losses of $565,708 and $628,621 a year earlier. Operating expenses were $220,496 for the quarter, driven by research and development of $157,733 and general and administrative costs of $62,763. Stock-based compensation remained significant at $68,706 for the quarter, though lower than the prior-year period.
Cash used in operating activities reached $263,415 in the first half of 2026. As of June 30, 2026, cash and cash equivalents were $419,365 and short-term investments were $271,313, against an accumulated deficit of $2,699,283. Management states that this liquidity is not sufficient to fund planned operations for at least one year and that these conditions raise substantial doubt about the company’s ability to continue as a going concern, making additional financing critical.
The company’s strategy centers on ivonescimab, a bispecific PD-1/VEGF-A antibody being developed across multiple Phase III trials in non-small cell lung and colorectal cancers. In EGFR‑mutated NSCLC after EGFR-TKI therapy, the HARMONi trial showed a progression free survival hazard ratio of 0.52, while overall survival trended favorably but did not reach statistical significance. A Biologics License Application for this setting has been accepted by the FDA with a Prescription Drug User Fee Act goal action date of November 14, 2026; the FDA has cautioned that a statistically significant overall survival benefit is expected for approval.
Summit Therapeutics reported a sharply higher net loss and raised going concern doubts in its latest quarter. For the three months ended March 31, 2026, the company recorded a net loss of $189.4 million versus $62.9 million a year earlier, driven by intensive development spending on its lead cancer drug ivonescimab and a large increase in stock-based compensation.
Research and development expenses rose to $132.6 million, while general and administrative costs climbed to $62.6 million. Summit held $106.5 million in cash and cash equivalents and $492.2 million in short-term investments, which it states are insufficient to fund planned operations for at least one year, creating substantial doubt about its ability to continue as a going concern. The FDA has accepted the Biologics License Application for ivonescimab in EGFR-mutated lung cancer, with a Prescription Drug User Fee Act action date of November 14, 2026, but has indicated that a statistically significant overall survival benefit is necessary for potential approval.
Summit Therapeutics Inc. reported a large increase in operating activity as it advances ivonescimab, its lead bispecific antibody licensed from Akeso. The company recorded cash and cash equivalents of $297,872 (reported in thousands) and total assets of $324,037, while total stockholders' equity decreased to $259,439. For the three and six months ended June 30, 2025, Summit reported net losses of $(565,708) and $(628,621) (in thousands), respectively, with basic and diluted net loss per share of $(0.76) and $(0.85) for the three- and six-month periods.
Clinical progress is material: Summit announced topline HARMONi Phase III results showing a statistically significant improvement in progression-free survival (PFS) with ivonescimab plus chemotherapy (hazard ratio 0.52; 95% CI 0.41–0.66; p<0.00001) and a positive, non-significant overall survival trend (HR 0.79; p=0.057). The company intends to consider filing a BLA. Liquidity and going-concern items are notable: management states cash is not sufficient to fund planned operations for at least one year, and the filing discloses substantial doubt about the company’s ability to continue as a going concern.